Using genetics to inform the pharmacological targeting of neuroendocrine neoplasms.

Abstract:

:Neuroendocrine neoplasms (NEN) are a class of tumours heterogeneous in terms of their anatomical sites of origin and clinical behaviour. Outdated perspectives of indolence have been superseded by appreciation for their myriad clinical challenges, such as the high rates of regional and distant metastases at initial diagnosis, lack of clarity on optimal treatment strategies/sequencing, and incompletely elucidated genetic/other pathophysiological drivers. The first randomised controlled trials in this arena were published approximately a decade ago - since then, increased understanding of the genetic drivers and signalling pathway perturbations in these tumours have suggested promise for precision therapy influenced by an individual tumour's molecular sub-type, but this is yet to be realised for manifold reasons. In this article, the authors review the genetic landscapes as currently understood for selected forms of NEN and discuss the current and developing evidence to support the use of genetic information to influence therapy. They provide a critical assessment of the potential limitations of using such approaches and also posit avenues for future developments in this arena.

journal_name

Endocr Relat Cancer

journal_title

Endocrine-related cancer

authors

Clift AK,Frilling A

doi

10.1530/ERC-20-0074

subject

Has Abstract

pub_date

2020-09-01 00:00:00

pages

R293-R305

issue

9

eissn

1351-0088

issn

1479-6821

pii

ERC-20-0074.R2

journal_volume

27

pub_type

杂志文章,评审
  • The natural history and treatment of non-functioning pituitary adenomas (non-functioning PitNETs).

    abstract::Non-functioning pituitary adenomas, recently alternatively termed pituitary neuroendocrine tumours (NFpitNETs), are mostly benign neoplasms that are not associated with a hormonal hypersecretory syndrome. The clinical spectrum of NFpitNETs varies from completely asymptomatic to the development of panhypopituitarism an...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1530/ERC-20-0136

    authors: Yavropoulou MP,Tsoli M,Barkas K,Kaltsas G,Grossman A

    更新日期:2020-10-01 00:00:00

  • Stem cells in genetically-engineered mouse models of prostate cancer.

    abstract::The cancer stem cell model proposes that tumors have a hierarchical organization in which tumorigenic cells give rise to non-tumorigenic cells, with only a subset of stem-like cells able to propagate the tumor. In the case of prostate cancer, recent analyses of genetically engineered mouse (GEM) models have provided e...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1530/ERC-15-0367

    authors: Shibata M,Shen MM

    更新日期:2015-12-01 00:00:00

  • The ubiquitin-proteasome system: opportunities for therapeutic intervention in solid tumors.

    abstract::The destruction of proteins via the ubiquitin-proteasome system is a multi-step, complex process involving polyubiquitination of substrate proteins, followed by proteolytic degradation by the macromolecular 26S proteasome complex. Inhibitors of the proteasome promote the accumulation of proteins that are deleterious t...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1530/ERC-14-0005

    authors: Johnson DE

    更新日期:2015-02-01 00:00:00

  • MAPK and SHH pathways modulate type 3 deiodinase expression in papillary thyroid carcinoma.

    abstract::Type 3 deiodinase (DIO3, D3) is reactivated in human neoplasias. Increased D3 levels in papillary thyroid carcinoma (PTC) have been associated with tumor size and metastatic disease. The objective of this study is to investigate the signaling pathways involved in DIO3 upregulation in PTC. Experiments were performed in...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-15-0162

    authors: Romitti M,Wajner SM,Ceolin L,Ferreira CV,Ribeiro RV,Rohenkohl HC,Weber Sde S,Lopez PL,Fuziwara CS,Kimura ET,Maia AL

    更新日期:2016-03-01 00:00:00

  • Pathways of chemotherapy resistance in castration-resistant prostate cancer.

    abstract::Chemotherapy remains the major treatment option for castration-resistant prostate cancer (CRPC) and limited cytotoxic options are available. Inherent chemotherapy resistance occurs in half of all patients and inevitably develops even in those who initially respond. Docetaxel has been the mainstay of therapy for 6 year...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1530/ERC-10-0343

    authors: Mahon KL,Henshall SM,Sutherland RL,Horvath LG

    更新日期:2011-07-04 00:00:00

  • Autotaxin is an inflammatory mediator and therapeutic target in thyroid cancer.

    abstract::Autotaxin is a secreted enzyme that converts extracellular lysophosphatidylcholine to lysophosphatidate (LPA). In cancers, LPA increases tumour growth, metastasis and chemoresistance by activating six G-protein coupled receptors. We examined >200 human thyroid biopsies. Autotaxin expression in metastatic deposits and ...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-15-0045

    authors: Benesch MG,Ko YM,Tang X,Dewald J,Lopez-Campistrous A,Zhao YY,Lai R,Curtis JM,Brindley DN,McMullen TP

    更新日期:2015-08-01 00:00:00

  • MicroRNA applications for prostate, ovarian and breast cancer in the era of precision medicine.

    abstract::The high degree of conservation in microRNA from Caenorhabditiselegans to humans has enabled relatively rapid implementation of findings in model systems to the clinic. The convergence of the capacity for genomic screening being implemented in the prevailing precision medicine initiative and the capabilities of microR...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1530/ERC-16-0525

    authors: Smith B,Agarwal P,Bhowmick NA

    更新日期:2017-05-01 00:00:00

  • New drugs for medullary thyroid cancer: new promises?

    abstract::Medullary thyroid cancer (MTC) is a rare tumor arising from the calcitonin-producing parafollicular C cells of the thyroid gland, occurring either sporadically or alternatively in a hereditary form based on germline RET mutations in approximately one-third of cases. Historically, patients with advanced, metastasized M...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1530/ERC-16-0104

    authors: Spitzweg C,Morris JC,Bible KC

    更新日期:2016-06-01 00:00:00

  • Elevated CSF1 serum concentration predicts poor overall survival in women with early breast cancer.

    abstract::Colony-stimulating factor 1 (CSF1) is a key regulator of mammary gland development, and a modulator of tissue macrophages. Expression of the CSF1 receptor gene C-FMS (CSF1R) is strongly associated with poor outcome in breast cancer and results in tumor cell invasiveness and pro-metastatic behavior in vitro. However, C...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-13-0198

    authors: Aharinejad S,Salama M,Paulus P,Zins K,Berger A,Singer CF

    更新日期:2013-10-14 00:00:00

  • Annual fasting plasma glucose variation increases risk of cancer incidence and mortality in patients with type 2 diabetes: the Taichung Diabetes Study.

    abstract::The study aims to examine whether the annual variations in fasting plasma glucose (FPG) measurements, represented by the coefficient of variation (CV), predict cancer incidence and mortality in the subsequent years independent of traditional risk factors of type 2 diabetic patients. A computerized database of patients...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-12-0038

    authors: Lin CC,Li CI,Liu CS,Lin WY,Chen CC,Yang SY,Lee CC,Li TC

    更新日期:2012-07-18 00:00:00

  • A new appraisal of iodine refractory thyroid cancer.

    abstract::Thyroid cancer incidence is increasing all over the world - mostly due to an increase in the detection of small tumors that were previously undetected. A small percentage of these tumors lose the ability to uptake and/or to respond to radioiodine (RAI) therapy, especially in metastatic patients. There are several new ...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1530/ERC-15-0300

    authors: Vaisman F,Carvalho DP,Vaisman M

    更新日期:2015-12-01 00:00:00

  • FOXO factors and breast cancer: outfoxing endocrine resistance.

    abstract::The majority of metastatic breast cancers cannot be cured and present a major public health problem worldwide. Approximately 70% of breast cancers express the estrogen receptor, and endocrine-based therapies have significantly improved patient outcomes. However, the development of endocrine resistance is extremely com...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1530/ERC-15-0461

    authors: Bullock M

    更新日期:2016-02-01 00:00:00

  • Beyond peroxisome proliferator-activated receptor gamma signaling: the multi-facets of the antitumor effect of thiazolidinediones.

    abstract::Certain members of the thiazolidinedione (TZD) family of the peroxisome proliferator-activated receptor gamma (PPARgamma) agonists, such as troglitazone and ciglitazone, exhibit antitumor activities; however, the underlying mechanism remains inconclusive. Substantial evidence suggests that the antiproliferative effect...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1677/erc.1.01182

    authors: Weng JR,Chen CY,Pinzone JJ,Ringel MD,Chen CS

    更新日期:2006-06-01 00:00:00

  • mTOR inhibitors response and mTOR pathway in pancreatic neuroendocrine tumors.

    abstract::Medical therapy of pancreatic neuroendocrine tumors (P-NET) may take advantage of Everolimus treatment. However, the extent of therapeutic response cannot be predicted. This study was aimed to identify the possible predictive markers of response to Everolimus in P-NET. We found that Everolimus reduced the cell viabili...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-16-0329

    authors: Falletta S,Partelli S,Rubini C,Nann D,Doria A,Marinoni I,Polenta V,Di Pasquale C,Degli Uberti E,Perren A,Falconi M,Zatelli MC

    更新日期:2016-11-01 00:00:00

  • MicroRNAs: a complex regulatory network drives the acquisition of malignant cell phenotype.

    abstract::Several lines of evidence indicate that tumorigenesis is a complex multistep process, and that most, if not all, cancers acquire the same set of functional capabilities during development and progression, albeit through various mechanistic strategies. Increasing data show an important role of microRNAs (miRNAs or miRs...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1677/ERC-09-0222

    authors: Santarpia L,Nicoloso M,Calin GA

    更新日期:2010-01-29 00:00:00

  • Identification of occult tumors by whole-specimen mapping in solitary papillary thyroid carcinoma.

    abstract::We undertook this study to estimate an accurate incidence and spread patterns of occult papillary thyroid carcinoma (PTC) in patients with a preoperative diagnosis of solitary PTC by using whole-specimen mapping of all specimens after a total thyroidectomy. Enrolled prospectively in this whole-thyroid mapping study ar...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-15-0152

    authors: Park SY,Jung YS,Ryu CH,Lee CY,Lee YJ,Lee EK,Kim SK,Kim TS,Kim TH,Jang J,Park D,Dong SM,Kang JG,Lee JS,Ryu J

    更新日期:2015-08-01 00:00:00

  • Overcoming oncogene addiction in breast and prostate cancers: a comparative mechanistic overview.

    abstract::Prostate cancer (PCa) and breast cancer (BCa) are both hormone-dependent cancers that require the androgen receptor (AR) and estrogen receptor (ER, ESR1) for growth and proliferation, respectively. Endocrine therapies that target these nuclear receptors (NRs) provide significant clinical benefit for metastatic patient...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1530/ERC-20-0272

    authors: Blatt EB,Kopplin N,Kumar S,Mu P,Conzen SD,Raj GV

    更新日期:2020-12-01 00:00:00

  • Phase III trial of chemotherapy using 5-fluorouracil and streptozotocin compared with interferon alpha for advanced carcinoid tumors: FNCLCC-FFCD 9710.

    abstract::The aim of this randomized multicenter phase III trial was to compare chemotherapy and interferon (IFN) in patients with metastatic carcinoid tumors. Patients with documented progressive, unresectable, metastatic carcinoid tumors were randomized between 5-fluorouracil plus streptozotocin (day 1-5) and recombinant IFN-...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1677/ERC-09-0104

    authors: Dahan L,Bonnetain F,Rougier P,Raoul JL,Gamelin E,Etienne PL,Cadiot G,Mitry E,Smith D,Cvitkovic F,Coudert B,Ricard F,Bedenne L,Seitz JF,Fédération Francophone de Cancérologie Digestive (FFCD).,Digestive Tumors Group of the F

    更新日期:2009-12-01 00:00:00

  • Estrogen and antiestrogen regulation of cell cycle progression in breast cancer cells.

    abstract::The central involvement of estrogen in the development of the mammary gland and in the genesis of breast cancer has lent impetus to studies of the links between estrogen action and the cell cycle machinery. Recent studies of the estrogenic regulation of molecules with known roles in the control of G1/S phase progressi...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1677/erc.0.0100179

    authors: Doisneau-Sixou SF,Sergio CM,Carroll JS,Hui R,Musgrove EA,Sutherland RL

    更新日期:2003-06-01 00:00:00

  • Tumour-associated fibroblasts contribute to neoangiogenesis in human parathyroid neoplasia.

    abstract::Components of the tumour microenvironment initiate and promote cancer development. In this study, we investigated the stromal component of parathyroid neoplasia. Immunohistochemistry for alpha-smooth muscle actin (α-SMA) showed an abundant periacinar distribution of α-SMA(+) cells in normal parathyroid glands (n=3). T...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-14-0161

    authors: Verdelli C,Avagliano L,Creo P,Guarnieri V,Scillitani A,Vicentini L,Steffano GB,Beretta E,Soldati L,Costa E,Spada A,Bulfamante GP,Corbetta S

    更新日期:2015-02-01 00:00:00

  • Uncontrolled insulin secretion from a childhood pancreatic beta-cell adenoma is not due to the functional loss of ATP-sensitive potassium channels.

    abstract::We report the case of an 8-year-old child who presented with severe hyperinsulinaemic hypoglycaemia due to a pancreatic islet cell adenoma. In vivo, there was no beneficial response to the hyperglycaemia-inducing agent diazoxide and as a consequence the child underwent a subtotal pancreatectomy. In vitro studies of ad...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1677/erc.0.0090221

    authors: Hussain K,Cosgrove KE,Shepherd RM,Chapman JC,Swift SM,Smith VV,Kassem SA,Glaser B,Lindley KJ,Aynsley-Green A,Dunne MJ

    更新日期:2002-12-01 00:00:00

  • Distinctive functions of p160 steroid receptor coactivators in proliferation of an estrogen-independent, tamoxifen-resistant breast cancer cell line.

    abstract::Elevated expression of steroid receptor coactivator-3 (SRC-3), a member of the p160 family of nuclear receptor coactivators, has been implicated in tamoxifen resistance of breast tumors while the involvement of the two other members of this family, SRC-1 and SRC-2, is less well characterized. In this study, using smal...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1677/ERC-09-0285

    authors: Karmakar S,Foster EA,Blackmore JK,Smith CL

    更新日期:2010-12-21 00:00:00

  • Potentiated anti-tumor effects of BETi by MEKi in anaplastic thyroid cancer.

    abstract::Anaplastic thyroid cancer (ATC) is an aggressive malignancy with limited treatment options. We explored novel treatment modalities by targeting epigenetic modifications using inhibitors of BET (e.g. BRD4) activity. We evaluated the efficacy in the treatment of ATC of a novel BET inhibitor, PLX51107 (PLX), currently in...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-19-0107

    authors: Zhu X,Park S,Lee WK,Cheng SY

    更新日期:2019-09-01 00:00:00

  • Ki-67 index, tumor differentiation, and extent of liver involvement are independent prognostic factors in patients with liver metastases of digestive endocrine carcinomas.

    abstract::The prognosis remains ill-defined in patients with liver metastases of well-differentiated (WD) digestive endocrine carcinomas (DEC) with high Ki-67 index. The objectives of this study were to determine whether Ki-67 index, tumor differentiation, and extent of liver involvement are independent prognostic factors in pa...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1677/ERC-09-0319

    authors: Hentic O,Couvelard A,Rebours V,Zappa M,Dokmak S,Hammel P,Maire F,O'Toole D,Lévy P,Sauvanet A,Ruszniewski P

    更新日期:2010-12-13 00:00:00

  • Effect of low doses of estradiol and tamoxifen on breast cancer cell karyotypes.

    abstract::Evidence supports a role of 17&-estradiol (E2) in carcinogenesis and the large majority of breast carcinomas are dependent on estrogen. The anti-estrogen tamoxifen (TAM) is widely used for both treatment and prevention of breast cancer; however, it is also carcinogenic in human uterus and rat liver, highlighting the p...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-16-0078

    authors: Rondón-Lagos M,Rangel N,Di Cantogno LV,Annaratone L,Castellano I,Russo R,Manetta T,Marchiò C,Sapino A

    更新日期:2016-08-01 00:00:00

  • Y-box binding protein-1 promotes castration-resistant prostate cancer growth via androgen receptor expression.

    abstract::The androgen receptor (AR) is well known to play a central role in the pathogenesis of prostate cancer (PCa). In several studies, AR was overexpressed in castration-resistant PCa (CRPC). However, the mechanism of AR overexpression in CRPC is not fully elucidated. Y-box binding protein-1 (YB-1) is a pleiotropic transcr...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-11-0017

    authors: Shiota M,Takeuchi A,Song Y,Yokomizo A,Kashiwagi E,Uchiumi T,Kuroiwa K,Tatsugami K,Fujimoto N,Oda Y,Naito S

    更新日期:2011-07-11 00:00:00

  • Identification of a paired box gene 8-peroxisome proliferator-activated receptor gamma (PAX8-PPARgamma) rearrangement mosaicism in a patient with an autonomous functioning follicular thyroid carcinoma bearing an activating mutation in the TSH receptor.

    abstract::Our main objective was to search for mutations in candidate genes and for paired box gene 8-peroxisome proliferator-activated receptor gamma (PAX8-PPARgamma) rearrangement in a well-differentiated angioinvasive follicular thyroid carcinoma (FTC) causing hyperthyroidism. DNA and RNA were extracted from the patient's th...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1677/ERC-09-0069

    authors: Lado-Abeal J,Celestino R,Bravo SB,Garcia-Rendueles ME,de la Calzada J,Castro I,Castro P,Espadinha C,Palos F,Soares P,Alvarez CV,Sobrinho-Simões M,Cameselle-Teijeiro J

    更新日期:2010-06-03 00:00:00

  • HEREDITARY ENDOCRINE TUMOURS: CURRENT STATE-OF-THE-ART AND RESEARCH OPPORTUNITIES: Early thyroidectomy in multiple endocrine neoplasia: a four decade experience.

    abstract::Forty years ago, physicians caring for the J-kindred, a 100+ member family with multiple endocrine neoplasia type 2A (MEN2A), hypothesized that early thyroidectomy based on measurement of the biomarker calcitonin could cure patients at risk for development of medullary thyroid carcinoma (MTC). We re-evaluated 22 famil...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-20-0108

    authors: Grubbs EG,Lechan RM,Edeiken-Monroe B,Cote GJ,Trotter C,Tischler AS,Gagel RF

    更新日期:2020-08-01 00:00:00

  • Factors regulating the growth of metastatic cancer in bone.

    abstract::Metastatic tumor cells can interfere directly with the function of bone cells involved in normal bone remodeling or indirectly by influencing the behavior of hematopoietic, stromal and other cells in bone marrow that interact with bone cells. Recent studies of metastatic cancer have revealed that tumor cells interact ...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1677/erc.0.0060333

    authors: Boyce BF,Yoneda T,Guise TA

    更新日期:1999-09-01 00:00:00

  • Somatostatin receptor subtype 5 (SSTR5) mRNA expression is related to histopathological features of cell proliferation in insulinomas.

    abstract::Insulinomas are rare endocrine neoplasias that constitute the most frequent islet cell tumours. Somatostatin (SST) analogs are tentatively used to inhibit insulin secretion and control tumour growth in patients with local invasion or inoperative metastasis, but variable responses have been reported. Data regarding som...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1677/erc.1.00962

    authors: de Sá SV,Corrêa-Giannella ML,Machado MC,de Souza JJ,Pereira MA,Patzina RA,Siqueira SA,Machado MC,Giannella-Neto D

    更新日期:2006-03-01 00:00:00